Assenagon Asset Management S.A. Has $1.46 Million Position in Organogenesis (NASDAQ:ORGO)

Assenagon Asset Management S.A. lowered its stake in shares of Organogenesis (NASDAQ:ORGO - Free Report) by 88.6% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 336,963 shares of the company's stock after selling 2,613,886 shares during the quarter. Assenagon Asset Management S.A. owned about 0.27% of Organogenesis worth $1,456,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Merit Financial Group LLC bought a new stake in Organogenesis during the first quarter worth approximately $45,000. Virtu Financial LLC bought a new stake in Organogenesis during the fourth quarter worth approximately $38,000. ProShare Advisors LLC boosted its position in Organogenesis by 49.0% during the fourth quarter. ProShare Advisors LLC now owns 20,329 shares of the company's stock worth $65,000 after purchasing an additional 6,689 shares during the period. Algert Global LLC bought a new stake in shares of Organogenesis in the fourth quarter valued at approximately $69,000. Finally, PDT Partners LLC bought a new stake in shares of Organogenesis in the fourth quarter valued at approximately $110,000. Institutional investors own 49.57% of the company's stock.

Analysts Set New Price Targets

Separately, Morgan Stanley increased their price objective on Organogenesis from $4.00 to $6.00 and gave the company an "equal weight" rating in a research report on Wednesday, March 5th.

Insider Buying and Selling

In other news, insider Lori Freedman bought 100,863 shares of Organogenesis stock in a transaction that occurred on Wednesday, June 4th. The stock was purchased at an average cost of $2.82 per share, with a total value of $284,433.66. Following the completion of the transaction, the insider now directly owns 695,058 shares in the company, valued at $1,960,063.56. This trade represents a 16.97% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders bought a total of 252,264 shares of company stock valued at $725,732 over the last ninety days. 33.00% of the stock is owned by company insiders.

Organogenesis Stock Performance

Shares of ORGO traded down $0.04 during mid-day trading on Friday, hitting $3.23. The company's stock had a trading volume of 1,494,584 shares, compared to its average volume of 1,143,311. Organogenesis has a one year low of $2.28 and a one year high of $6.71. The firm has a market capitalization of $409.73 million, a PE ratio of -19.00 and a beta of 1.63. The stock's 50-day moving average is $3.68 and its two-hundred day moving average is $3.80.

Organogenesis (NASDAQ:ORGO - Get Free Report) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($0.17). Organogenesis had a negative net margin of 3.46% and a negative return on equity of 4.00%. The business had revenue of $86.69 million during the quarter, compared to the consensus estimate of $90.77 million. Analysts expect that Organogenesis will post -0.07 EPS for the current fiscal year.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.